Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.34 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.34 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 6/20 | 0.34 |
| ▸ | RAB9A | P51151 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28509833 | 0.85 | CTNNB1 (0.35) | NPC1RAB9AP4HBHTTTP53 | |
| SCHEMBL27192092 | 0.78 | ACVRL1 (0.36) | AOC3CYP3A4TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL29950897 | 0.74 | AOC3 (0.39) | AOC3CYP3A4TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL1224244 | 0.74 | AOC3 (0.39) | AOC3CYP3A4TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL8798169 | 0.74 | AOC3 (0.41) | AOC3CYP3A4TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL25166479 | 0.71 | AOC3 (0.42) | AOC3CYP3A4TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL1172231 | 0.71 | TXNRD1 (0.37) | AOC3CYP3A4TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL30049221 | 0.71 | AOC3 (0.42) | AOC3CYP3A4TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL12865269 | 0.71 | NQO2 (0.40) | AOC3TXNRD1TXNRD3TXNRD2NPC1 | |
| SCHEMBL28506707 | 0.71 | TXNRD1 (0.37) | AOC3CYP3A4TXNRD1TXNRD3TXNRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| EP-3883570-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | HCCS, HAVCR2, HDGF | AOC3 3664/4885CYP3A4 109/4885TXNRD1 1875/4885 |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | AOC3 3664/4885CYP3A4 109/4885TXNRD1 1875/4885 |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | AOC3 3664/4885CYP3A4 109/4885TXNRD1 1875/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | AOC3 3664/4885CYP3A4 109/4885TXNRD1 1875/4885 |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | AOC3 3664/4885CYP3A4 109/4885TXNRD1 1875/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | AOC3 3664/4885CYP3A4 109/4885TXNRD1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.